Isarna Therapeutics GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Isarna Therapeutics GmbH
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced October 2015.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced April through May 2014.
Following a Phase III disappointment with its lead anticancer candidate, Germany’s Isarna Therapeutics has garnered new funding to advance its preclinical pipeline of oligonucleotides targeting TGF-beta.
Cell therapy firm Apceth has appointed Dr Stefanos Theoharis to the newly created position of chief business officer. Prior to joining Munich, Germany-based Apceth – a developer of stem cell-based therapies for the treatment of malignant and non-malignant diseases – Dr Theoharis was head of business development at Antisense Pharma.
- Antisense, Oligonucleotides
- Large Molecule
- Other Names / Subsidiaries
- Antisense Pharma GmbH